NOCDURNA has been studied for years

Proven clinical trial experience

  • NOCDURNA has been evaluated in a long-term clinical trial of up to 3 years1

MOST COMMON ADVERSE REACTIONS

Common adverse reactions (reported in >2% of NOCDURNA-treated patients) in clinical trials 1, 2, and 31

Women Men
Adverse Reaction* Placebo
(N=173)
NOCDURNA
27.7 mcg
(N=196)
Placebo
(N=213)
NOCDURNA
55.3 mcg
(N=195)
Dry Mouth 19 (11%) 23 (12%) 27 (13%) 27 (14%)
Hyponatremia 3 (2%) 6 (3%) 1 (<1%) 8 (4%)
Headache 5 (3%) 4 (2%) 3 (1%) 7 (4%)
Dizziness 0 3 (2%) 1 (<1%) 5 (3%)
Women
Adverse Reaction* Placebo
(N=173)
NOCDURNA
27.7 mcg
(N=196)
Dry Mouth 19 (11%) 23 (12%)
Hyponatremia 3 (2%) 6 (3%)
Headache 5 (3%) 4 (2%)
Dizziness 0 3 (2%)
Men
Adverse Reaction* Placebo
(N=213)
NOCDURNA
55.3 mcg
(N=195)
Dry Mouth 27 (13%) 27 (14%)
Hyponatremia 1 (<1%) 8 (4%)
Headache 3 (1%) 7 (4%)
Dizziness 1 (<1%) 5 (3%)
  1. Includes adverse reactions occurring during up to 3 months of treatment in patients who continued from Study 3 into Study 4.

The most common adverse reactions reported with both the 27.7 mcg/day and 55.3 mcg/day dosages included dry mouth, hyponatremia or blood sodium decrease, headache, and dizziness.1

The high incidence of dry mouth may have been affected by specific query about dry mouth in Study 3. In Studies 1 and 2 where the adverse reaction was spontaneously reported, the incidence was ≤4%.1

Reference: 1. NOCDURNA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.